POD1UM-202: This phase II trial is assessing how effective a new intravenous therapy (INCMGA00012) is in treating patients with squamous carcinoma of the anal canal (SCAC) who have gotten worse after chemotherapyA Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

Exclusion

• Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug; 6 weeks for mitomycin C.
• Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy, 6 months for thoracic region radiotherapy that is > 30 Gy.
• Prior treatment with programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy.
• Active autoimmune disease requiring systemic immunosuppression.
• Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Known active hepatitis infection.
• Active infections requiring systemic therapy.
• Is pregnant or breastfeeding or is expecting to conceive or father children within the projected duration of the study, from screening through 6 months after the last dose of study drug.